ArrayExpress Uploader0humanpre-tx0.2mg per kg24h post tx0.2mg per kgpre-tx0.2mg per kg24h post tx0.2mg per kg4weeks post tx0.2mg per kgpre-tx2mg per kg24h post tx2mg per kg4weeks post tx2mg per kgpre-tx6mg per kg24h post tx6mg per kg4h post tx6mg per kgpre-tx0.2mg per kg24h post tx0.2mg per kg4weeks post tx0.2mg per kgpre-tx1mg per kg24h post tx1mg per kg4weeks post tx1mg per kgpre-tx2mg per kg24h post tx2mg per kg4weeks post tx2mg per kgpre-tx4mg per kg24h post tx4mg per kg4weeks post tx4mg per kgpre-tx2mg per kg24h post tx2mg per kg4weeks post tx2mg per kgpre-tx4mg per kg24h post tx4mg per kg4h post tx4mg per kg4weeks post tx4mg per kgpre-tx6mg per kg24h post tx6mg per kgpre-tx4mg per kg24h post tx4mg per kg4weeks post tx4mg per kgpre-tx4mg per kg24h post tx4mg per kgpre-tx6mg per kg24h post tx6mg per kg4h post tx6mg per kgpre-tx4mg per kg24h post tx4mg per kg4h post tx4mg per kg4weeks post tx4mg per kgpre-tx4mg per kg24h post tx4mg per kg4h post tx4mg per kg4weeks post tx4mg per kgpre-tx6mg per kg24h post tx6mg per kg4h post tx6mg per kg4weeks post tx6mg per kgpre-tx6mg per kg24h post tx6mg per kg4h post tx6mg per kg4weeks post tx6mg per kg3991arrayexpress_sid4SPC2996 is a novel locked nucleic acid (LNA) phosphorothioate antisense molecule targeting the mRNA of the Bcl-2 oncoprotein. We...E-GEOD-27858/profile/8773/arrayexpressuploader256chronic lymphocytic leukemialeukemiaperipheralDec.12, 2014FalseE-GEOD-27858_A-AFFY-44the-novel-antisense-bcl-2-inhibitor-spc2996-causesThe novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemiaSep.15, 2014SPC2996 is a novel locked nucleic acid (LNA) phosphorothioate antisense molecule targeting the mRNA of the Bcl-2 oncoprotein. We investigated the mechanism of action of SPC2996 and the basis for its clinically observed immunostimulatory effects in chronic lymphocytic leukemia (CLL). Patients with relapsed CLL were treated with a maximum of six doses of SPC2996 (0.2-6mg/ kg) in a multicenter phase I trial. Microarray-based transcriptional profiling of circulating CLL cells was carried out before and after the first infusion of SPC2996 in eighteen patients. We used microarrays to characterize global gene expression changes of circulating CLL cells in response to SPC2996 infusion in 18 patients Key word : Response to therapeutic agent We performed microarray-based gene expression profiling in serial peripheral blood samples from 18 individual CLL patients before and after treatment with SPC2996http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-27858http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-27858/samples/